Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)27.97bn
- Net income in JPY2.44bn
- Incorporated2006
- Employees603.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nxera Pharma Co Ltd | 16.43bn | -9.07bn | 134.76bn | 350.00 | -- | 2.04 | -- | 8.20 | -107.30 | -107.30 | 194.96 | 736.60 | 0.1309 | -- | 5.77 | 46,954,280.00 | -7.23 | -0.6588 | -7.78 | -0.7036 | 74.44 | 89.83 | -55.20 | -4.46 | 4.03 | -10.91 | 0.5238 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
Sumitomo Pharma Co Ltd | 314.56bn | -314.97bn | 137.67bn | 6.25k | -- | 0.8808 | -- | 0.4377 | -792.79 | -792.79 | 791.76 | 392.82 | 0.308 | 1.21 | 3.76 | -- | -30.84 | -5.07 | -54.58 | -7.73 | 59.76 | 69.99 | -100.12 | -12.28 | 0.2992 | -- | 0.7285 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
Towa Pharmaceutical Co Ltd | 227.93bn | 16.17bn | 152.13bn | 4.30k | 8.99 | 0.9324 | 6.15 | 0.6674 | 328.58 | 328.58 | 4,630.88 | 3,167.26 | 0.5684 | 1.51 | 3.66 | -- | 4.03 | 4.21 | 5.03 | 5.63 | 35.70 | 39.23 | 7.10 | 7.23 | 1.46 | -- | 0.5649 | 20.79 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Kissei Pharmaceutical Co Ltd | 75.58bn | 11.16bn | 157.55bn | 1.80k | 12.96 | 0.6419 | 10.14 | 2.08 | 246.57 | 246.57 | 1,669.95 | 4,977.43 | 0.3135 | 1.56 | 2.94 | -- | 4.68 | 3.61 | 5.05 | 3.90 | 49.41 | 49.47 | 14.94 | 12.69 | 4.43 | -- | 0.006 | 34.69 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
KAKEN PHARMACEUTICAL CO., LTD. | 72.04bn | 8.03bn | 172.78bn | 1.13k | 17.68 | 0.9908 | 19.74 | 2.40 | 212.76 | 212.76 | 1,909.11 | 3,796.04 | 0.4264 | 2.05 | 3.37 | -- | 4.75 | 6.83 | 5.40 | 7.87 | 53.49 | 54.78 | 11.14 | 14.48 | 4.72 | -- | 0.0261 | 51.19 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
Nippon Shinyaku Co., Ltd. | 148.25bn | 25.85bn | 220.66bn | 2.19k | 8.18 | 0.9606 | 7.15 | 1.49 | 383.80 | 383.80 | 2,201.16 | 3,269.71 | 0.592 | 1.33 | 3.25 | -- | 10.32 | 10.45 | 12.09 | 12.31 | 66.12 | 61.27 | 17.44 | 16.47 | 3.35 | -- | 0.0129 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
Peptidream Inc | 27.97bn | 2.44bn | 263.40bn | 603.00 | 107.50 | 6.57 | 53.77 | 9.42 | 18.85 | 18.85 | 215.77 | 308.51 | 0.4323 | 4.20 | 5.14 | 46,391,190.00 | 3.77 | -- | 4.38 | -- | 59.16 | -- | 8.73 | -- | 3.23 | 2.59 | 0.3505 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
Sawai Group Holdings Co Ltd | 176.86bn | 17.22bn | 265.40bn | 3.39k | 15.45 | 1.25 | 8.64 | 1.50 | 392.06 | 311.79 | 4,029.61 | 4,854.95 | 0.474 | 1.21 | 2.85 | -- | 3.40 | 0.7104 | 4.60 | 0.9705 | 30.71 | 35.08 | 7.17 | 1.47 | 1.50 | 52.16 | 0.2755 | 88.14 | 8.04 | -0.8249 | 46.82 | -2.33 | 18.15 | 0.00 |
Tsumura & Co | 150.85bn | 16.71bn | 307.19bn | 4.03k | 18.21 | 1.12 | 10.67 | 2.04 | 219.81 | 219.81 | 1,984.75 | 3,566.54 | 0.3657 | 0.748 | 2.42 | -- | 4.37 | 4.81 | 5.43 | 5.89 | 45.62 | 50.98 | 11.96 | 12.65 | 2.39 | -- | 0.2125 | 32.09 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
Hisamitsu Pharmaceutical Co Inc | 141.71bn | 13.97bn | 323.97bn | 2.76k | 21.02 | 1.09 | 16.53 | 2.29 | 180.93 | 180.93 | 1,840.27 | 3,497.04 | 0.441 | 3.13 | 3.43 | 51,361,360.00 | 4.49 | 4.22 | 5.25 | 4.82 | 55.73 | 58.62 | 10.18 | 10.03 | 3.76 | -- | 0.0078 | 53.05 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
Holder | Shares | % Held |
---|---|---|
M&G Investment Management Ltd.as of 15 Dec 2023 | 9.80m | 7.54% |
Taiyo Pacific Partners LPas of 31 Dec 2023 | 6.58m | 5.06% |
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 14 Jul 2023 | 4.44m | 3.42% |
Nomura Asset Management Co., Ltd.as of 30 Apr 2024 | 3.26m | 2.51% |
The Vanguard Group, Inc.as of 09 May 2024 | 3.17m | 2.44% |
Baillie Gifford & Co.as of 30 Apr 2024 | 3.06m | 2.35% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.09m | 1.61% |
Nikko Asset Management Co., Ltd.as of 14 Jul 2023 | 1.80m | 1.39% |
Comgest SAas of 30 Jun 2023 | 1.75m | 1.35% |
Daiwa Asset Management Co. Ltd.as of 30 Apr 2024 | 1.54m | 1.18% |